Wyeth v. Lupin Ltd.’s Empirical Analysis
2007
Citation profile
1 federal appellate · 3 district ·
Relationships
Applies 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 35 U.S.C. § 271
Relies on Bell Atlantic Corp. v. Twombly · Papasan v. Allain · Mylan Laboratories, Inc. v. Matkari · Eli Lilly & Co. v. Medtronic, Inc. · Glaxo, Inc. v. Novopharm, Ltd.
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 5 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“[p]arties `actively involved' in preparing the ANDA are deemed to have `submitted' the ANDA, regardless of whether they are the named applicant; this is especially true where the parties involved are in the same corporate family. `Active involvement' includes `marketing and distributing the approved generic drugs in the United States.'”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.